Harvard Bioscience Inc. (HBIO) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Harvard Bioscience Inc. (HBIO:NASDAQ), powered by AI.

Current Price
$5.95
P/E Ratio
-4.7
Market Cap
264M
Sector
Healthcare
What is the Harvard Bioscience Inc. stock price forecast?

Harvard Bioscience Inc. is currently trading at $5.95. View real-time AI analysis on Alpha Lenz.

What is Harvard Bioscience Inc. insider trading activity?

View the latest insider trading data for Harvard Bioscience Inc. on Alpha Lenz.

What is Harvard Bioscience Inc.'s P/E ratio?

Harvard Bioscience Inc.'s P/E ratio is -4.7.

Harvard Bioscience Inc.

NASDAQ · HBIO
$5.95-0.04(-0.67%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Harvard Bioscience Inc.'s future dividend policy...
Alpha Chat Insight

Harvard Bioscience Inc. trades at a P/E of -4.7 (undervalued) with modest ROE of -147.1%.

Ask for details

Company Overview

Harvard Bioscience Inc. is a developer, manufacturer, and distributor of scientific instruments, consumables, and systems. The company's primary function is to facilitate advanced research, aiding life science professionals in their pursuits of cutting-edge scientific inquiries. Harvard Bioscience offers an extensive array of products, including apparatus for cell analysis, microfluidics, drug discovery, and bio-processing. These advanced devices are crucial for laboratories within sectors such as biotechnology, pharmaceuticals, and academic research institutions, helping to drive innovation and discovery in medical and life sciences. Headquartered in Holliston, Massachusetts, Harvard Bioscience holds a pivotal role in supplying essential tools and technologies that empower scientists and researchers worldwide. By continually evolving its product offerings, the company addresses the needs of an ever-changing market and supports the progression of scientific advancements that can impact global health outcomes. This makes Harvard Bioscience an integral component of the scientific research infrastructure, contributing significantly to technological and methodological developments in its field.

CEOMr. John Duke
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees330

Company Statistics

FY 2025

Profile

$264.13MMarket Cap
$86.55MRevenue
0.00Shares Out
330Employees

Margins

57.67%Gross
2.49%EBITDA
0.12%Operating
-66.30%Pre-Tax
-65.51%Net

Valuation

-4.66P/E
19.23P/B
3.05EV/Sales
139.05EV/EBITDA
54.28P/FCF

Growth (CAGR)

-8.60%Rev 3Yr
-3.25%Rev 5Yr
N/AOp Inc 3Yr
-14.67%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-54.86%ROA
-147.13%ROE
-50.76%ROIC

Financial Health

$8.61MCash & Cash Equivalents
$57.72MNet Debt
483.01%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Harvard Bioscience Inc. (ticker: HBIO) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 330 employees. Market cap is $264M.

The current price is $5.95 with a P/E ratio of -4.66x and P/B of 19.23x.

ROE is -147.13% and operating margin is 0.12%. Annual revenue is $87M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Harvard Bioscience Inc. (HBIO) Stock Forecast 2026 $5.95 — Price, Financials & Analyst Targets | Alpha Lenz